Baragaña B; Forte B; Choi R; Hewitt SN; Bueren-Calabuig JA; Pisco JP; Peet C; Dranow DM; Robinson DA; Jansen C; Norcross NR; Vinayak S; Anderson M; Brooks CF; Cooper CA; Damerow S; Delves M; Dowers K; Duffy J; Edwards TE; Hallyburton I; Horst BG; Hulverson MA; Ferguson L; Jiménez-Díaz MB; Jumani RS; Lorimer DD; Love MS; Maher S; Matthews H; McNamara CW; Miller P; O’Neill S; Ojo KK; Osuna-Cabello M; Pinto E; Post J; Riley J; Rottmann M; Sanz LM; Scullion P; Sharma A; Shepherd SM; Shishikura Y; Simeons FRC; Stebbins EE; Stojanovski L; Straschil U; Tamaki FK; Tamjar J; Torrie LS; Vantaux A; Witkowski B; Wittlin S; Yogavel M; Zuccotto F; Angulo-Barturen I; Sinden R; Baum J; Gamo FJ; Mäser P; Kyle DE; Winzeler EA; Myler PJ; Wyatt PG; Floyd D; Matthews D; Sharma A; Striepen B; Huston CD; Gray DW; Fairlamb AH; Pisliakov AV; Walpole C; Read KD; Van Voorhis WC; Gilbert IH, 2019, 'Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis',
Proceedings of the National Academy of Sciences of the United States of America, vol. 116, pp. 7015 - 7020,
http://dx.doi.org/10.1073/pnas.1814685116